Cookie Policy

We've put some small files called essential cookies on your device to help our site work on your browser.
We also use analytical cookies to help up improve our website by collecting and reporting information on it's usage.

You can read more above this on our Privacy Policy page.

I'm ok with analytical cookies Do not use analytics cookies
Contact us

News

Stay up to date with the exciting new developments as we continue to grow.

The content of all investor relations materials contained on this website are deemed to be correct at the time of issue/publication.

Filter by date

9 Mar 2021

Australia’s Therapeutic Goods Administration (TGA) approves Feraccru® to treat Iron Deficiency with or without anaemia in adults

Shield Therapeutics plc, notes that Australia's Therapeutics Goods Administration has registered Feraccru® in the Australian Register of Therapeutic Goods to treat iron deficiency with or without anaemia in adults. Feraccru® is…

1 Mar 2021

Shareholder Placing/Subscription Circular and Notice of GM

Shield Therapeutics plc, Placing, Subscription and Open Offer of up to 97,279,730 New Shares at 30 pence per share and Notice of General Meeting. For…

26 Feb 2021

Successful completion of £25 million Fundraise

Shield Therapeutics plc, is pleased to announce the successful completion of the placing (the "Placing"), and the subscription (the “Subscription”) which were announced earlier today…

26 Feb 2021

Placing and Subscription to raise up to £25 million, Open Offer to raise up to £4.2 million and Notice of General Meeting

Shield Therapeutics plc, announces a proposed fundraising by way of a subscription (the “Subscription”) and placing (the "Placing") to raise up to £25.0 million in…

15 Jan 2021

Business and Trading Update

Shield Therapeutics plc, provides a business and unaudited trading update for the year ended 31 December 2020. For the full details click here.

10 Dec 2020

Shield considering launch of Accrufer® in the USA – Loan facilities agreed

Shield Therapeutics plc, provides an update on its plans to commercialise Accrufer® in the USA and its cash position. For full details click here.

19 Oct 2020

Withdrawal of all oppositions by Teva Pharmaceutical Industries Ltd

Shield Therapeutics plc, announces an update on its opposition proceedings with Teva Pharmaceutical Industries Ltd (TEVA). For further details click here.

16 Sep 2020

Half-year Report Interim Report for the six months ended 30 June 2020

Shield Therapeutics plc, announces its unaudited interim results for the six months ended 30 June 2020. For further details click here.

6 Aug 2020

Shield provides the headline results from the reanalysis of the AEGIS-H2H study.

Shield Therapeutics plc, provides the headline results from the reanalysis of the AEGIS-H2H study. For further details click here.